VERVNASDAQHealthcare · Biotechnology

Verve Therapeutics, Inc.

$11.13+0.27%(+$0.03)

TickerSpark Score

72/100

Solid

Valuation

Profitability

Growth

Health

100

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERV research report →

52-Week Range97% of range

Low $2.87

Current $11.13

High $11.40

Companywww.vervetx.com

Verve Therapeutics, Inc. , a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.

CEO: Sekar Kathiresan
IPO: 2021
Employees: 274
HQ: Boston, MA, US

Price Chart

+44.55% · this period

Valuation

Market Cap: $994.04M
P/E: -12.19
P/S: 21.58
P/B: 2.09
EV/EBITDA: -10.82
Div Yield: 0.00%

Profitability

Gross Margin: 100.00%
Op Margin: -201.28%
Net Margin: -176.02%
ROE: -16.77%
ROIC: -16.19%

Growth & Income

Revenue: $32.33M · 174.98%
Net Income: $-198,709,000 · 0.68%
EPS: $-2.36 · 24.36%
Op Income: $-228,660,000
FCF YoY: -1.63%

Performance & Tape

52W High: $11.40
52W Low: $2.87
50D MA: $8.21
200D MA: $6.45
Beta: 2.24
Avg Volume: 5.72M

Get TickerSpark's AI analysis on VERV

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Jul 25, 25	GV 2017 GP, L.L.C.	10 percent owner	other	1,800,000	$18.90M
Jul 25, 25	MacLean Michael F	director	sell	136,139	$683.42K
Jul 25, 25	MacLean Michael F	director	sell	42,200	$241.81K
Jul 25, 25	Yeshwant Krishna	director, 10 percent owner:	sell	136,139	$683.42K
Jul 25, 25	Yeshwant Krishna	director, 10 percent owner:	sell	42,200	$241.81K
Jul 25, 25	Yeshwant Krishna	director, 10 percent owner:	other	1,800,000	$18.90M
Jul 25, 25	Dorval Allison	officer: Chief Financial Officer	sell	75,000	$450.75K
Jul 25, 25	Dorval Allison	officer: Chief Financial Officer	other	13,280	$139.44K
Jul 25, 25	Dorval Allison	officer: Chief Financial Officer	sell	1,875	$0
Jul 25, 25	Dorval Allison	officer: Chief Financial Officer	sell	180,000	$2.29M

Our VERV Coverage

View all →

Top Stocks

Top Gene Editing Stocks: Our 7 Picks for 2026

These seven gene editing stocks span CRISPR leaders, base and prime editors, and in vivo delivery plays, with CRISPR Therapeutics ranking highest on overall investment quality.

May 21, 2026